An Open-Label Study of Nefazodone in the Treatment of Depression With and Without Comorbid Obsessive Compulsive Disorder

References

• Pritchard JC: A treatise on Insanity. London: Sherwood, Gil-bert and Piper; 1835:18, 22,35
   Google Scholar
• Esquirol E: "Monomanie." Des Maladies Mentales. Paris: Bailliere, 1838; Vol 2
   Google Scholar
• Marc CCH: De la Folie Consideree dans ses Rapports avec les Questions Medicojudiciaries, 1840,1:238 ff
   Google Scholar
• Gittleson NL: The effect of obsessions on depressive psycho-sis. Br J Psychiatry 1966; 112:253–259
   Google Scholar
• Gittleson NL: The phenomenology of obsessions in depressive psychosis. Br J Psychiatry 1966; 112:261–264
   Google Scholar
• Gittleson NL: The fate of obsessions in depressive psychosis. Br J Psychiatry 1966; 112:705–708
   Google Scholar
• Gittleson NL: Depressive psychosis in the obsessional neu-rotic. Br J Psychiatry 1966; 112:883–887
   PubMedGoogle Scholar
• Gittleson NL: The relationship between obsessions and suici-dal attempts in depressive psychosis. Br J Psychiatry 1966; 112:889–890
   Google Scholar
• Rasmussen S, Eisen J: Clinical and epidemiologic findings of significance to neuropharmacologic trials in OCD. Psycho-pharmacol Bull 1988; 24:466–470
   PubMedGoogle Scholar
• Freed A, Kerr TA, Roth M: The treatment of obsessional neurosis. Br J Psychiatry 1972; 120:590–591
   Google Scholar
• Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L: Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37:1281–1285
   PubMed Web of Science ®Google Scholar
• Ananth J, Pecknold JC, Van Dan Steen N, Engelsmann F: Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychophar-macol 1981; 5:257–262
   PubMedGoogle Scholar
• Volavka J, Neziroglu F, Yaryura-Tobias JA: Clomipramine and imipramine in obsessive compulsive disorder. Psychiatry Res 1985; 14:85–93
   PubMed Web of Science ®Google Scholar
• Zohar J, Inset TR: Obsessive-compulsive disorder: Psychobi-ological approaches to diagnosis, treatment, and pathophysi-ology. Biol Psychiatry 1987; 22:667–687
   PubMed Web of Science ®Google Scholar
• Marks IM, Stern RS, Mawson D, Cobb J, McDonald R: Clomipramine and exposure for obsessive compulsive rituals, I. Br J Psychiatry 1980; 136:1–25
   PubMed Web of Science ®Google Scholar
• Insel TR, Murphy DL, Cohen RM, Alterman L, Kilts C, Lin-noila M: Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40:605–612
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Turner SM, Michelson L, Jacob R: Tricyclic antidepressants in obsessive compulsive disorder: Antiobses-sional or antidepressant agents? II. Am J Psychiatry 1985; 142:572–576
   PubMed Web of Science ®Google Scholar
• Foa EB, Steketee GL, Kozak MJ, Dugger DD: Imipramine and placebo in the treatment of obsessive-compulsives: Their effect on depression and on obsessional symptoms. Psycho-pharmacol Bull 1987; 23:8–11
   PubMedGoogle Scholar
• DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Ras-mussen S: Clinical predictors of treatment responses in ob-sessive-compulsive disorder: Exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull 1990; 26:54–59
   PubMedGoogle Scholar
• Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD: Nefazodone: Preclinical pharmacology of a new antidepres-sant. Psychopharmacol Bull 1990; 26:311–315
   PubMed Web of Science ®Google Scholar
• Feighner JP, Pambakian R, Fowler RC, Boyer WR, D'Arnico MF: A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychophar-macol Bull 1989; 25:219–221
   PubMed Web of Science ®Google Scholar
• D'Amico MF, Roberts DL, Robinson DS, Schwiderski UE, Copp J: Placebo-controlled dose-ranging trial designs in phase II development of Nefazodone. Psychopharmacol Bull 1990; 26:147–150
   PubMed Web of Science ®Google Scholar
• Rickles K, Schweizer E, Clary C, Fox I, Fox I, Weise C: Ne-fazodone and imipramine in major depression: A placebo-controlled trial. Br J Psychiatry 1994; 164:802–805
   Google Scholar
• Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G: A Double-blind comparison of Nefazodone, Imipramine and placebo in major depression. J Clin Psychiatry 1994; 55:234–241
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (third edition-revised). Wash-ington, DC: American Psychiatric Association; 1987
   Google Scholar
• Mattes JA: A Pilot study of combined Trazodone and Tryp-tophan in obsessive-compulsive disorder. Int Clin Psycho-pharmacol 1986; 1:170–173
   PubMed Web of Science ®Google Scholar
• Prasad A: Efficacy of Trazodone as an anti-obsessional agent. Neuropsychobiology 1986; 15:19–21
   Google Scholar
• Hermesh H, Aizenberg D, Munitz H: Trazodone treatment in clomipramine resistant obsessive-compulsive disorder. Clin Neuropharmacol 1990; 13:322–328
   PubMedGoogle Scholar
• Spitzer RL, Williams JBW, Gibbon M, First MB: Structured Clinical Interview for DSM-III-R--Patient Edition (SCID-P,9/1/89 Version). Biometrics Research Department; 1989
   Google Scholar
• Hamilton M: Development of a rating scale for primary de-pressive illness. Br J Soc Psychol 1967; 6:278–296
   Google Scholar
• Hamilton M: Diagnosis and ratings of anxiety. Br J Psychiatry 1969; 3:76–79
   Google Scholar
• Goodman WK, Price LH, Rasmussen SA, Masure C, Fleish-mann C, Hill C, Heninger G, Charney D: The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). II: Validity. Arch Gen Psychiatry 1989; 46:1012–1016
   PubMed Web of Science ®Google Scholar
• The Clomipramine Collaborative Study Group: Clomipramine in the treatment of patients with obsessive compulsive disor-der. Arch Gen Psychiatry 1991; 48:730–738
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Hollander E, Schneier F, Campeas R, Hat-terer J, Papp L, Fairbanks J, Sandberg D, Davies S, Stein M: Fluoxetine treatment of obsessive compulsive disorder: Psychiatry 1989; 146:909–911
   Google Scholar